Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction by Streng, Koen W. et al.
International Journal of Cardiology 271 (2018) 132–139
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdNon-cardiac comorbidities in heart failure with reduced, mid-range and
preserved ejection fraction☆Koen W. Streng a, Jan F. Nauta a, Hans L. Hillege a, Stefan D. Anker b, John G. Cleland c, Kenneth Dickstein d,e,
Gerasimos Filippatos f, Chim C. Lang g, Marco Metra h, Leong L. Ng i, Piotr Ponikowski j, Nilesh J. Samani i,
Dirk J. van Veldhuisen a, Aeilko H. Zwinderman k, Faiez Zannad l, Kevin Damman a,
Peter van der Meer a, Adriaan A. Voors a,⁎
a University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
b Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Centre Göttingen (UMG), Göttingen, Germany
c National Heart & Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, UK
d University of Bergen, Bergen, Norway
e Stavanger University Hospital, Stavanger, Norway
f National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, Athens, Greece
g School of Medicine Centre for Cardiovascular and Lung Biology, Division of Medical Sciences, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK
h Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy
i Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, UK
j Department of Heart Diseases, Wroclaw Medical University, Poland and Cardiology Department, Military Hospital, Wroclaw, Poland
k Department of Epidemiology, Biostatistics and Bioinformatics, Academic Medical Centre, Amsterdam, The Netherlands
l Inserm CIC 1433, Université de Lorrain, CHU de Nancy, Nancy, France☆ All authors take responsibility for all aspects of the reli
the data presented and their discussed interpretation.
⁎ Corresponding author at: Department of Cardiolo
Groningen, Hanzeplein 1, 9713 GZ Groningen, The Nether
E-mail address: a.a.voors@umcg.nl (A.A. Voors).
https://doi.org/10.1016/j.ijcard.2018.04.001
0167-5273/© 2018 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 30 October 2017
Received in revised form 19 March 2018
Accepted 2 April 2018
Available online 7 July 2018Background: Comorbidities play a major role in heart failure. Whether prevalence and prognostic importance of
comorbidities differ between heart failure with preserved ejection fraction (HFpEF), mid-range (HFmrEF) or
reduced ejection fraction (HFrEF) is unknown.
Methods: Patients from index (n = 2516) and validation cohort (n = 1738) of The BIOlogy Study to TAilored
Treatment in Chronic Heart Failure (BIOSTAT-CHF)were pooled. Eight non-cardiac comorbidities were assessed;
diabetes mellitus, thyroid dysfunction, obesity, anaemia, chronic kidney disease (CKD, estimated glomerular
filtration rate b 60 mL/min/1.73 m2), COPD, stroke and peripheral arterial disease. Patients were classified
based on ejection fraction. The association of each comorbidity with quality of life (QoL), all-cause mortality
and hospitalisation was evaluated.
Results: Patients with complete comorbidity data were included (n= 3499). Most prevalent comorbidity was
CKD (50%). All comorbidities showed the highest prevalence in HFpEF, except for stroke. Prevalences of HFmrEF
were in between the other entities. COPD was the comorbidity associated with the greatest reduction in QoL. In
HFrEF, almost all were associated with a significant reduction in QoL, while in HFpEF only CKD and obesity were
associatedwith a reduction. Most comorbidities in HFrEFwere associatedwith an increasedmortality risk, while
in HFpEF only CKD, anaemia and COPD were associated with higher mortality risks.
Conclusions: The highest prevalence of comorbidities was seen in patients with HFpEF. Overall, comorbidities
were associated with a lower QoL, but this was more pronounced in patients with HFrEF. Most comorbidities
were associated with higher mortality risks, although the associations with diabetes were only present in
patients with HFrEF.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Heart failure (HF) is often accompanied by one or multiple non-
cardiac comorbidities, making diagnosis and management of HF more
complicated. These comorbidities are often associated with worse out-
comes andhigher hospitalisation rates [1–3]. It is known that HF and co-
morbidities such as chronic kidney disease (CKD, defined as glomerularthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nary disease (COPD), diabetes mellitus, stroke and anaemia are often
present in HF, and that CKD is associated with an increased mortality
risk [4,5]. Studies have shown that comorbidities are more prevalent,
are associated with a higher mortality risk and with more physical
impairment in patients with heart failure with preserved ejection frac-
tion (HFpEF) compared with patients with a reduced ejection fraction
(HFrEF) [6–8]. However, the association of each of the separate comor-
bidities with mortality in patients with HF is currently unknown.
Secondly, little is known about the association of individual non-
cardiac comorbidities with quality of life (QoL) in patients with HFrEF,
HFpEF and heart failure with mid-range ejection fraction (HFmrEF).
This study therefore aimed to investigate the associations between
individual non-cardiac comorbidities and QoL and their association
with mortality in patients with HFrEF, HFmrEF and HFpEF.
2. Methods
2.1. Study population
For the current study population, we have combined both the index cohort (n= 2516)
and validation cohort (n= 1738) of theBIOSTAT-CHF (A systems BIOlogy Study to Tailored
Treatment in Chronic Heart Failure), a multicentre, prospective observational study [9]. In
the index cohort, primary inclusion criteria were an objective cardiac dysfunction, defined
by either a left ventricular ejection fraction (LVEF) b40% or plasma N-terminal pro-brain
natriuretic peptide (NT-proBNP) of N2000 pg/mL and be treated with at least 40 mg of
furosemide or equivalent, and were on sub-optimal dose of angiotensin-converting
enzyme inhibitors and/or angiotensin receptor blockers. Main inclusion criteria in the
validation cohort were documented HF and patients had to be treated with at least 20mg
furosemide or equivalent per day and were anticipated to be up titrated with ACE inhibi-
tors/ARBs and/or beta-blockers. Institutional review board approved the study, and all pa-
tients gave written informed consent. A full list of inclusion and exclusion criteria has
been previously published [9]. Patients were divided based on LVEF into HFrEF
(LVEFb40%), HFmrEF (LVEF 40–50%) and HFpEF (LVEF ≥50%) according to themost recent
ESCHF guidelines [10]. Patientswho had full data available for the 8 non-cardiac comorbid-
ities stated below and who had available LVEF were included (n= 3499).
2.2. Non-cardiac comorbidities
Eight non-cardiac comorbidities were included in this analysis. Comorbidities included
were diabetesmellitus (type I and type II diabetes), obesity (defined as a bodymass index
above or equal to 30 kg/m2), thyroid dysfunction (both hypo- and hyperthyroid disease),
chronic kidney disease (CKD) (defined as an estimated glomerular filtration rate (eGFR)
b60 mL/min/1.73 m2) measured at baseline, a history of stroke, chronic obstructive
pulmonary disease (COPD), peripheral arterial disease (PAD) and anaemia (defined as a
haemoglobin below 12 g/dL in woman and below 13 g/dL in men, measured at baseline)
[11]. The presence of COPD, stroke, thyroid dysfunction, PAD or diabeteswas assessed by the
treating physicians, based on information available on the patients' medical history and dur-
ing inclusion of the study.
2.3. Statistical analysis
Normally distributed data arepresented asmeans andstandard deviation, not normally
distributed data as medians and 25th until 75th percentile, and categorical variables as
percentages and frequencies. Intergroup differences between variables were tested using
one-way ANOVA for normal distributed data; skewed data was tested using Chi-squared
test or Kruskal-Wallis test depending on whether the data was continuous or nominal.
Post-hoc analysis was performed to calculate differences between the groups. Prevalence
of each of the comorbidities was also standardized for age. Age groups were created per
10 years, starting at 20 years up to 100 years. Per age group, the age specific prevalence
in each of the HF subgroups was assessed, and multiplied by the total number of patients
in that age category. This was done for each of the age groups, after which the sum of all
the age groupswas divided by the total number of patients. QoLwas assessed by using the
Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQol five dimensions ques-
tionnaire (EQ-5D) [12,13]. A difference of ≥5 points betweenmean scores was considered
to beminimally clinically important [13,14]. To evaluate the association of the comorbid-
ities with KCCQ overall score, univariable and multivariable linear regression analysis
was performed. Cox proportional hazard analysis was performed to analyze the different
hazard ratios with 95% confidence interval (CI) per comorbidity. These were depicted in a
forest plot combined with a P-value for interaction. All hazard ratios were corrected for
age, sex, NYHA class and physical limitation score.
A two-sided P-value b0.05 was considered statistically significant.
All analyses were performed using IBM SPSS Statistics version 23 and R: a Language
and Environment for Statistical Computing, version 3.0.2. (R Foundation for Statistical
Computing, Vienna, Austria).3. Results
3.1. Baseline characteristics
A total of 3499 patients were included in our current study. Baseline
characteristics are shown in Table 1. We included 2309 patients with
HFrEF (66%), 634 with HFmrEF (18%) and 556 patients with HFpEF
(16%). Patients with HFpEF were older, more often women, and had
higher systolic blood pressures (P b 0.001). Patients with HFrEF were
less likely to have a history of hypertension (57%). CKD was present in
50% of patients, anaemia in 36%, obesity and diabetes mellitus in 33%,
COPD in 18%, and stroke and thyroid dysfunction in 13% of the patients
(Fig. 1). In general, the prevalences of comorbidities were greater in
HFpEF, compared with HFmrEF and HFrEF. CKD (56%) and anaemia
(46%) had the highest prevalence in HFpEF (respectively P = 0.002
and P b 0.001). COPD was present in 24% of HFpEF patients and 17% in
patients with HFrEF (P b 0.001). A history of stroke was found more
often in HFmrEF (17%). The prevalence of diabetes differed between
HFpEF andHFrEF, where the prevalencewithin HFmrEFwas in between
HFpEF and HFrEF, but not significantly different. The prevalences of the
other comorbidities are shown in Table 1. The number of comorbidities
in patients with HFrEF, HFmrEF and HFpEF differed significantly
(P b 0.001). Patients with HFpEF had the highest number of comorbidi-
ties, while patients with HFrEF had the lowest number of comorbidities
(Supplementary Fig. 1). At least 1 comorbidity was found in 84% of the
patients with HFrEF, while this was 87% in HFmrEF patients and 94% in
patients with HFpEF (P b 0.001). Age-standardized prevalence for the
comorbidities is depicted in Supplementary Fig. 2.
3.2. Non-cardiac comorbidities and quality of life
Overall, QoL was lower in HFpEF compared with HFmrEF and HFrEF.
When assessing the different domains within the KCCQ, patients with
HFpEF had more physical limitations, more symptom frequency and
burden, and had themost social limitations (all P b 0.001). Most comor-
bidities were associated with a significant decline in mean KCCQ score
(all P b 0.001), but the decline in mean overall KCCQ score was larger
in patients with HFrEF and HFmrEF, compared with patients with
HFpEF (Table 2). In patients with HFrEF, each comorbidity, except for
thyroid dysfunction, was associated with a significant decline in mean
KCCQ score, while in patients with HFpEF COPD (P = 0.002), obesity
(P = 0.048) and thyroid dysfunction (P = 0.017) were associated
with a decline in QoL. Other comorbidities did not yield a significant
difference in mean KCCQ score. Supplementary Fig. 3 shows the differ-
ence in overall mean KCCQ score between the subgroups. A differ-
ence of ≥5 points was considered to be minimal clinically important.
In the total cohort, each of the comorbidities had a minimal clinically
important difference, where a decrease of 10 points in mean KCCQ
score was seen in patients with COPD. However, in patients with
HFrEF, obesity and thyroid dysfunction are no longer associated with
a difference in QoL, while the same was true for CKD in HFmrEF. In
contrast to the other HF groups, the only comorbidities with a minimal
clinical important difference in patients with HFpEF were COPD and
thyroid dysfunction. To evaluate the association of comorbidities with
QoL in the different HF groups, linear regression was performed
(Supplementary Table 1). Overall, each non-cardiac comorbidity was
associated with a lower KCCQ overall score (all P b 0.001, except for
thyroid dysfunction (P= 0.035)). Consistent in each of the HF groups,
both COPD and obesity were significantly associated with a lower
KCCQ score. However, diabetes was only associated with a lower
KCCQ score in HFrEF (P b 0.001), but not in HFmrEF and HFpEF. Both
CKD and anaemia were not associated with KCCQ score in HFpEF
(respectively P = 0.987 and P= 0.293).
The differences between the groups were less pronounced when
using the EQ-5D scale. When assessing the Visual Analog Scale (VAS)
score used in the EQ-5D in the total cohort, the presence of each
Table 1
Baseline characteristics.
HFrEF HFmrEF HFpEF Total P-value
N 2309 634 556 3499
Demographics
Sex (% male) 1744 (75.5) 416 (65.6) 300 (54.0) 2460 (70.3) b0.001
Age (years) 69 ± 12.2 75 ± 11.1 78 ± 9.8 71 ± 12 b0.001
Systolic blood pressure (mmHg) 123 ± 21 129 ± 22 130 ± 23 125 ± 22 b0.001
Diastolic blood pressure (mmHg) 74 ± 13 72 ± 14 69 ± 14 72 ± 13 b0.001
Heart rate (beats/min) 79 ± 19 75 ± 19 76 ± 18 78 ± 19 b0.001
NT-proBNP (ng/L) 3054 [1158–6930] 1839 [603–4228] 1559 [511–3998] 2390 [842–5672] b0.001
Non-cardiac comorbidities
Diabetes mellitus (%) 722 (31.3) 221 (34.9) 198 (35.6) 1141 (32.6) 0.060
Thyroid dysfunction (%) 252 (10.9) 87 (13.7) 97 (17.4) 436 (12.5) b0.001
Stroke (%) 256 (11.1) 107 (16.9) 91 (16.4) 454 (13.0) b0.001
COPD (%) 384 (16.6) 103 (16.2) 132 (23.7) 619 (17.7) b0.001
CKD (%) 1115 (48.3) 334 (52.7) 312 (56.1) 1761 (50.3) 0.002
Anaemia (%) 758 (32.8) 254 (40.1) 253 (45.5) 1265 (36.2) b0.001
Obesity (%) 679 (29.4) 233 (36.8) 235 (42.3) 1147 (32.8) b0.001
Peripheral arterial disease (%) 323 (14.0) 127 (20.0) 135 (24.3) 585 (16.7) b0.001
Number of comorbidities 1.8 ± 1.3 2.1 ± 1.4 2.4 ± 1.3 2.0 ± 1.3 b0.001
Medical history
Hypertension (%) 1303 (56.5) 443 (70.0) 386 (69.4) 2132 (60.9) b0.001
Myocardial infarction (%) 998 (43.2) 303 (47.8) 181 (32.6) 1482 (42.4) b0.001
PCI (%) 471 (20.4) 128 (20.2) 89 (16.0) 688 (19.7) 0.044
CABG (%) 398 (17.2) 129 (20.3) 77 (13.9) 604 (17.3) 0.022
Atrial fibrillation (%) 996 (43.2) 313 (49.5) 275 (49.6) 1584 (45.3) b0.001
NYHA class b0.001
I 135 (5.8) 34 (5.4) 16 (2.9) 185 (5.3)
II 1074 (46.5) 270 (42.7) 194 (34.9) 1538 (44.0)
III 770 (33.3) 239 (37.8) 235 (42.3) 1244 (35.6)
IV 130 (5.6) 60 (9.5) 89 (16.0) 279 (8.0)
Quality of life
KCCQ
Physical limitation 54 [29–79] 50 [25–75] 42 [21–67] 50 [29–75] b0.001
Symptom stability 52 [25–75] 50 [25–75] 50 [25–75] 50 [25–75] 0.008
Symptom frequency 50 [25–70] 45 [25–70] 35 [15–60] 45 [25–70] b0.001
Symptom burden 42 [27–60] 40 [20–60] 33 [20–53] 40 [20–60] b0.001
Self-efficacy score 75 [50–88] 75 [50–88] 75 [50–88] 75 [50–88] b0.001
Quality of life 42 [25–67] 50 [25–67] 42 [25–67] 42 [25–67] 0.134
Social limitation 35 [15–60] 30 [10–55] 25 [5–50] 35 [15–55] b0.001
Overall score 47 [31–64] 43 [30–59] 38 [24–53] 44 [30–61] b0.001
EQ-5D
VAS score 55 [40–70] 59 [48–70] 52 [45–70] 55 [45–70] 0.359
Values are given as means± standard deviation, median (25th to 75th percentiles) or percentage and frequency.
HFrEF=Heart failurewith reduced ejection fraction; HFmrEF=Heart failure withmid-range ejection fraction; HFpEF=Heart failure with preserved ejection fraction; NTpro-BNP=N-terminal
pro brain natriuretic peptide; COPD = Chronic obstructive pulmonary disease; CKD = Chronic kidney disease; PCI = Percutaneous coronary intervention; CABG = Coronary
artery bypass graft; NYHA = New York Heart Association; KCCQ = Kansas City Cardiomyopathy Questionnaire.
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(P= 0.115). In patients with HFrEF, the presence of COPD (P b 0.001),
stroke (P= 0.039), diabetes (P b 0.001), CKD (P= 0.003) and anaemia
(P b 0.001) lowers the VAS score. In HFmrEF patients, only anaemia
(P = 0.003) is associated with a lower VAS, while in HFpEF only pa-
tients with COPD (P = 0.002) or thyroid dysfunction (P = 0.009) had
a significantly lower VAS score.
3.3. Non-cardiac comorbidities and outcome
In the overall cohort, all comorbidities were associated with
increased risk for all-cause mortality, except for stroke. Mean
follow-up was 25 months. Fig. 2 shows a forest plot with hazard
ratios for all-cause mortality and for hospitalisation per HF subgroup.
For hospitalisation, the only comorbidity with an increased hazard
ratio in HFpEF was thyroid dysfunction, while in HFmrEF CKD, diabetes
mellitus, thyroid dysfunction, COPD and anaemia were significantly
associated with increased hospitalisation risks. HFrEF showed similar
results as in HFmrEF.
Furthermore, in all HF subgroups the presence of CKDwas associated
with increased risk of mortality (HFpEF Hazard ratio (HR) 1.39, 95% CI
1.03 to 1.87, P = 0.032, HFmrEF HR 1.79, 95% CI 1.32 to 2.43, P b 0.001and HFrEF HR 1.49, 95% CI 1.25 to 1.77, P b 0.001, respectively). In
HFrEF, diabetesmellitus, anaemia and COPDwere all associatedwith sig-
nificantly higher event rates. In HFmrEF, besides anaemia (P b 0.001) no
other comorbidities were significantly related with higher mortality
rates. In HFpEF, COPD and thyroid dysfunction were both associated
with significantly increased event rates. For obesity, a decreased
mortality risk was seen in HFpEF (HR 0.60, 95% CI 0.44 to 0.80,
P b 0.001) and in HFmrEF (HR 0.66, 95% CI 0.48 to 0.89, P = 0.008). A
significant interaction between comorbidity and LVEF as a continuous
variable were seen for diabetes mellitus (P = 0.031) and anaemia
(P = 0.043). Diabetes and anaemia had a stronger association with
poor outcomes in HFrEF and HFmrEF, compared with HFpEF.
4. Discussion
We studied 8 non-cardiac comorbidities in a broad cohort of patients
with HF. Comorbidities with the greatest prevalence were the presence
of CKD, anaemia, diabetes and obesity. For all comorbidities, except for
stroke, the prevalence was the highest in patients with HFpEF. We
have further shown that most comorbidities were associated with
lower QoL, although the difference compared with not having the co-
morbidity was generally larger in patients with HFrEF compared with
Fig. 1. Prevalence of non-cardiac comorbidities in heart failure groups.
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associated with an increased risk of mortality, although the presence of
diabetes was only associated with higher mortality risks in HFrEF.
4.1. Prevalence of non-cardiac comorbidities
The most common comorbidities in this cohort were CKD and anae-
mia. These findings are in linewith previous studies, where a prevalence
of CKD in different cohorts of patients with HF is seen, ranging from 28%
up to 55% [1,4,15]. Prevalence of anaemia varies widely in the literature,
with numbers ranging from 5 to 60%, in concordance with our study
[16,17]. Obesity was present in 33% of our cohort, and its prevalence
was particularly high in patients with HFpEF. Obesity is more often
seen in patients with HFpEF, and could trouble the diagnosis of HF in
these patients [18]. However in our study, patients with HFpEF alsoTable 2
Quality of life in HF subgroups.
HFrEF P-value HFmrEF
Comorbidity present? No Yes No Yes
KCCQ overall score
COPD 50 [32–65] 37 [25–53] b0.001 45 [31–61] 36 [22–47]
Stroke 48 [31–64] 41 [24–60] b0.001 44 [30–60] 39 [29–51]
Diabetes 50 [33–66] 41 [26–58] b0.001 45 [31–61] 39 [28–56]
Obesity 48 [32–64] 44 [28–62] 0.011 46 [32–62] 39 [27–56]
Thyroid dysfunction 47 [31–64] 44 [29–60] 0.202 45 [31–60] 34 [24–53]
CKD 51 [33–67] 43 [28–60] b0.001 46 [31–64] 41 [28–56]
Anaemia 49 [33–66] 42 [27–58] b0.001 46 [32–64] 39 [28–51]
PAD 48 [31–64] 42 [27–58] 0.001 45 [31–61] 37 [28–52]
EQ-5D VAS score
COPD 60 [45–70] 50 [40–65] b0.001 60 [49–70] 50 [43–65]
Stroke 56 [43–70] 50 [40–70] 0.039 60 [49–70] 50 [40–70]
Diabetes 60 [45–70] 50 [40–70] b0.001 60 [49–70] 55 [45–70]
Obesity 55 [43–70] 59 [40–70] 0.737 60 [48–70] 55 [47–70]
Thyroid dysfunction 55 [40–70] 55 [40–70] 0.708 60 [49–70] 50 [40–70]
CKD 60 [45–70] 52 [40–70] 0.003 59 [49–70] 59 [46–70]
Anaemia 60 [45–70] 50 [40–70] b0.001 60 [50–71] 50 [45–70]
PAD 55 [41–70] 50 [40–70] 0.266 60 [47–70] 50 [48–70]
Values are given asmedian [25th to 75th percentiles]; HFrEF=Heart failurewith reduced ejectio
with preserved ejection fraction; KCCQ=Kansas city cardiomyopathy questionnaire; COPD=
arterial disease; EQ-5D=EuroQol five dimensions questionnaire.had increased levels of NT-proBNP, making misdiagnosis of HF much
more unlikely. Diabetes was present in 33% of patients, which is similar
to previous studies which report a prevalence ranging from 22% up to
45% [7,19,20]. Novel findings were the prevalences of non-cardiac
comorbidities in patients with HFmrEF. To the best of our knowledge,
this has not been described before. Prevalences of comorbidities showed
a gradual increase fromHFrEF toHFmrEF toHFpEF. Oneof our consistent
findingswas the fact that comorbidities weremore prevalent in patients
with HFpEF. Although two previous studies have depicted that non-
cardiac comorbidities were more prevalent in patients with HFpEF
[6,7], our study additionally focussed on the individual association of
each of the comorbidities with QoL and all-cause mortality. To assess
whether the higher prevalence of comorbidities in patients with
HFpEF was driven by age, we calculated age-standardized prevalences,
showing largely similar results. Only for CKD, the similarity inP-value HFpEF P-value Total P-value
No Yes No Yes
b0.001 41 [27–56] 30 [19–43] b0.001 46 [31–63] 36 [24–49] b0.001
0.098 39 [24–54] 34 [23–52] 0.362 45 [30–63] 39 [25–55] b0.001
0.039 38 [24–55] 37 [22–51] 0.350 47 [31–64] 40 [26–57] b0.001
0.004 40 [24–56] 36 [24–50] 0.048 46 [31–63] 41 [27–58] b0.001
0.002 39 [24–55] 34 [21–48] 0.017 45 [30–63] 40 [25–56] b0.001
0.010 37 [25–52] 38 [23–54] 0.767 48 [31–65] 42 [28–58] b0.001
b0.001 38 [24–56] 37 [24–52] 0.676 47 [31–65] 41 [27–56] b0.001
0.016 39 [24–53] 36 [22–52] 0.472 45 [30–63] 40 [26–55] b0.001
0.078 58 [50–70] 50 [40–60] 0.002 60 [45–70] 50 [40–65] b0.001
0.088 55 [45–70] 50 [40–65] 0.191 56 [45–70] 50 [40–70] 0.004
0.204 52 [40–70] 53 [50–70] 0.839 60 [45–70] 50 [40–70] 0.001
0.118 59 [45–70] 50 [40–70] 0.106 55 [45–70] 55 [40–70] 0.115
0.220 55 [45–70] 50 [41–60] 0.009 58 [45–70] 50 [40–70] 0.044
0.492 55 [43–70] 51 [46–69] 0.370 60 [45–70] 52 [40–70] 0.002
0.003 55 [45–70] 50 [45–68] 0.145 60 [45–70] 50 [40–70] b0.001
0.179 55 [45–70] 50 [43–70] 0.748 55 [45–70] 50 [40–70] 0.117
n fraction;HFmrEF=Heart failurewithmid-range ejection fraction; HFpEF=Heart failure
Chronic obstructive pulmonary disease; CKD=Chronic kidney disease; PAD= Peripheral
Fig. 2. Forest plotwith hazard ratios for all-causemortality (top) and hospitalisation (bottom) and each comorbidity; corrected for age, sex, NYHA class andphysical limitation. On the right
is P-value for interaction with heart failure group.
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age driven, as after age adjustment CKD was more frequently observed
in patients with HFrEF. For all other comorbidities the prevalence
remained greater in patients with HFpEF. Furthermore, multi-
morbidity was a common finding in our cohort, especially in patients
with HFpEF. Braunstein et al. previously showed that nearly 40% of
chronic HF patients had 5 or more comorbidities [2]. The prevalence
of (multiple) comorbidities increased rapidly during the past two de-
cades [21–23]. In our present study, multiple comorbidities were
more often present in patients with HFpEF. This could partly be due to
an older age, however, precisemechanisms behind non-cardiac comor-
bidities and HF are still unclear. However, they do seem an important
target for a more holistic approach in the treatment of HFpEF patients
[24].
Novel findings in our study also regard the prevalence and associa-
tions of comorbidities within HFmrEF. This entity is often referred to
as the middle child, which holds true in our cohort for the prevalence
of the different comorbidities. The prevalence for each comorbidity
was in between HFpEF and HFrEF. A recent review on HFmrEF studies
found that HFmrEF might be more similar to HFrEF, especially with
regard to the prevalence of IHD [25]. We also found that hazard ratio's
for the different comorbidities for HFmrEF showed a more similar
pattern to HFrEF compared with HFpEF.
4.2. Influence of comorbidities on quality of life
Comorbidities could influence QoL in several ways [26,27]. The ma-
jority of these non-cardiac comorbidities require the use of
medication, and polypharmacy is associated with a decrease in func-
tional status of the patient [28]. Furthermore, the majority of these
comorbidities are accompanied by a variety of (physical) symptoms,
such as fatigue, decrease in general condition and/or shortness of
breath. These factors not only limit the patients in functional status,
but could also influence their social status andwith that an even further
decline in QoL. Here, we indeed showed that comorbidities were associ-
atedwith a lower QoL. In amultivariable analysis, thereweremore indi-
vidual comorbidities that were independently associated with overall
KCCQ score in HFrEF comparedwith HFpEF patients. Since comorbidities
had a higher prevalence in patients with HFpEF, analyses were repeated
within a matched cohort for number of comorbidities with HFrEF. This
did not yield any significant difference. A plausible explanation could
be that the non-cardiac comorbidities were already present before the
onset of HFpEF, while in HFrEF the comorbidities were a consequence
of the HF itself. Although this cannot be concluded based on these data,
Paulus et al. have previously postulated that comorbidities in HFpEF in-
duce a pro-inflammatory state, resulting in alterations in myocardial
structure and functions. Consequently, the comorbidity itself might be
the cause -or deteriorating factor- in HFpEF [29]. Our findings might be
supportive of this theory.
One of the comorbidities consistently associated with QoL in all 3 HF
groups was COPD. HF and COPD often co-exist, with a
reported prevalence of approximately 20% within patients with HF.
COPD is known to be characterized by a low-grade state of inflamma-
tion, and may thus be associated with more frequent cardiovascular
events and therefore lowering QoL [30].
4.3. Influence of comorbidities on outcome
We found a consistent and strong association between the presence
of non-cardiac comorbidities and outcome. This finding is consistent
with previous studies in patients with chronic HF [4,31]. Overall,
CKD and anaemia were associated with the highest risks of all-cause
mortality. In patients with HFrEF, the presence of diabetes mellitus or
COPD was significantly associated with a worse outcome. The
presence of COPD may be associated with higher mortality risk in HF,
which could partially be due to the fact that patients with COPD areless likely to receive treatment with a beta-blocker and have a reduced
exercise capacity [32,33]. However, there are common shared denomi-
nators such as inflammation, smoking and/or chronic illness which are
known to cause both HF and comorbidities such as COPD [34].
Although in our cohort the association was borderline non-
significant, the association between a history of stroke and higher
mortality risk was previously shown in a cohort of patients with HFrEF
[35]. One reason for this association could be the shared risk factor of
atherosclerosis, or the development of thromboembolic events in pa-
tients with very low ejection fractions [36].
The precise mechanisms behind the increased mortality risks are
still unclear, however, there could be several factors involved in the
increased mortality risk observed in patients with (multiple) comor-
bidities. First of all, HF could result in more comorbidities. Due to
fatigue and shortness of breath, patients are more inactive which
could play a part in the development of for example diabetes and
obesity. Furthermore, patients with multiple comorbidities often
represent a more severe HF and are therefore associated with higher
mortality risks and higher hospitalisation rates. Lastly, comorbidities
may cause worsening HF via medication used to treat these comor-
bidities, or comorbidities may influence the use of HF medication,
influencing their effect on outcome in these patients.
The optimal treatment for both HF and the accompanying comor-
bidities is a clinical challenge. Especially in HFpEF, HF treatment options
are very limited. Therefore optimizing treatment of the separate comor-
bidities might at least improve the QoL of these patients. This hypothe-
siswill be investigated in a clinical trial, OPTIMIZE-HFPEF,which aims to
randomize patients to usual care or intensive treatment of several
common comorbidities in HFpEF [37]. It has been depicted in previous
research that, especially in HFpEF patients, a more targeted approach
might be necessary and therefore treating different phenotypes of
HFpEF by not only focussing on the symptoms of HF but also on concur-
rent comorbidities [38].4.4. Study limitations
Thiswas a retrospective, post-hoc study, combining two largeHF co-
horts. In this study in- and exclusion criteriawere used,whichmight re-
sult in a more selected population. The majority of patients was
recruited in-hospital, which might bias the QoL compared with outpa-
tients included. Another limitation concerns possible underreporting
of comorbidities, since they were assessed by the treating physician
and/or based on their reported medical history. For COPD, no
confirming spirometry was performed which could also result in a
false reporting of the comorbidity. Finally, the choice of comorbidities
analysed in our study was arbitrary, although this selection allowed us
to focus on specific non-cardiac comorbidities. Some comorbidities
were not assessed (for example obstructive sleep apnoea syndrome,
malignancy, depression and hepatic disease) since data on these comor-
bidities were not complete.5. Conclusion
We have studied 8 non-cardiac comorbidities in a broad cohort of
patients with HF. The most prevalent non-cardiac comorbidities were
CKD, anaemia, diabetes and obesity. The highest prevalence of comor-
bidities was seen in patients with HFpEF, whereas the prevalence in
HFmrEF was consistently in between HFpEF and HFrEF. While in the
overall group most of the comorbidities were associated with a lower
QoL, this association was more pronounced in patients with HFrEF
compared with patients with HFmrEF or HFpEF. Most comorbidities
were associated with higher mortality risks, however, the associations
with diabetes were only present in patients with HFrEF in contrast to
patients with HFmrEF or HFpEF.
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